STAAR Surgical (NASDAQ:STAA) Sets New 12-Month Low - What's Next?

STAAR Surgical (NASDAQ:STAA - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $23.10 and last traded at $23.10, with a volume of 412662 shares traded. The stock had previously closed at $24.54.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Canaccord Genuity Group decreased their target price on STAAR Surgical from $31.00 to $28.00 and set a "hold" rating for the company in a research report on Monday, December 9th. Finally, Stephens raised STAAR Surgical to a "hold" rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, STAAR Surgical has a consensus rating of "Hold" and a consensus target price of $42.83.

STAAR Surgical Trading Down 4.9 %

The business has a fifty day moving average of $26.69 and a 200-day moving average of $33.13. The firm has a market cap of $1.15 billion, a PE ratio of 53.02 and a beta of 0.63.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the firm's stock in a transaction on Wednesday, December 18th. The shares were purchased at an average cost of $24.33 per share, with a total value of $559,590.00. Following the completion of the purchase, the insider now owns 10,848,631 shares of the company's stock, valued at $263,947,192.23. The trade was a 0.21 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.00% of the company's stock.

Hedge Funds Weigh In On STAAR Surgical

Institutional investors and hedge funds have recently made changes to their positions in the business. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical during the third quarter valued at about $37,000. Quarry LP bought a new position in STAAR Surgical during the 3rd quarter worth approximately $50,000. Canada Pension Plan Investment Board bought a new position in STAAR Surgical during the 2nd quarter worth approximately $129,000. Larson Financial Group LLC purchased a new position in STAAR Surgical in the 2nd quarter worth approximately $130,000. Finally, Quest Partners LLC purchased a new stake in shares of STAAR Surgical during the third quarter valued at approximately $128,000. Institutional investors own 96.70% of the company's stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.